Neurodegenerative biomarkers outperform neuroinflammatory biomarkers in amyotrophic lateral sclerosis

Abstract

Biomarkers of neuroaxonal degeneration displayed better diagnostic and prognostic value compared with neuroinflammatory biomarkers. However, in contrast to spinal patients, in bulbar patients neurofilaments and CHIT1 performed worse at predicting survival and seemed to increase over time.